---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-016505"
form_type: "8-K"
ticker: "PLX"
cik: "0001006281"
company_name: "Protalix BioTherapeutics, Inc."
filed_at: "2024-12-31T23:59:59+00:00"
generated_at: "2026-05-28T19:29:02.125509+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Protalix BioTherapeutics amends bylaws to raise special meeting threshold to 25% and remove written consent

## Summary
- Stockholders now need 25% beneficial ownership (up from 10%) to call a special meeting.
- Company secretary must set meeting date at least 30 days after request (was 10 days).
- Stockholders can no longer act by written consent in lieu of a meeting.
- Exclusive forum provisions added: Delaware Chancery Court for state claims, federal courts for Securities Act claims.
- Enhanced procedural and disclosure requirements for stockholder proposals and director nominations.

## SEC filing metadata
- accession: 0001558370-24-016505
- form_type: 8-K
- ticker: PLX
- cik: 0001006281
- company_name: Protalix BioTherapeutics, Inc.
- filed_at: 2024-12-31T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 3.03, 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1006281/000155837024016505/0001558370-24-016505-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1006281/000155837024016505/plx-20241227x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-016505
- JSON: https://secwatch.observer/filing/0001558370-24-016505.json
- Plain text: https://secwatch.observer/filing/0001558370-24-016505.txt

## Key facts
- Governance Changes
  Protalix BioTherapeutics, Inc.: Amended and restated Bylaws to increase special meeting ownership threshold to 25%, modify timing, enhance procedural requirements for stockholder proposals and nominations, adopt universal proxy rules, remove written consent, and add exclusive forum provisions (effective 2024-12-27).
  - Change: bylaw amendment
  - Effective: 2024-12-27
  source text: On December 27, 2024, the Board of Directors of Protalix BioTherapeutics, Inc., a Delaware corporation (the “Company”), unanimously approved and adopted an amendment and restatement of the Bylaws of the Company, effective immediately (the “Amended Bylaws”) to, among other things: (i) amend the criteria relating to stockholders’ ability to call special meetings including (a) increasing the requisite aggregate beneficial ownership of the requesting stockholders from no less than 10% to no less than 25% of all of the votes entitled to be cast on any issue proposed to be considered at the special meeting, (b) modifying the time in which the Company’s secretary will fix the date of such special meeting from not less than 10 days to not less than 30 days after the receipt of such stockholder request, (c) modifying the time in which the stockholders making such request can set the special meeting date from seven days to 10 days following the receipt of such request if the Company’s secretary
  evidence_url: https://www.sec.gov/Archives/edgar/data/1006281/000155837024016505/0001558370-24-016505-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.